Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
37m
Zacks Small Cap Research on MSNNRXBF Test Results Bolster ProspectsNRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting ...
5hon MSN
Social media users and medical specialists have been raising awareness of a rare condition that stops people from burping, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results